Cheng Yu-Xi, Tao Wei, Kang Bing, Liu Xiao-Yu, Yuan Chao, Zhang Bin, Peng Dong
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Clinical Nutrition, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Front Surg. 2022 Mar 8;9:850265. doi: 10.3389/fsurg.2022.850265. eCollection 2022.
The current study aims to explore the outcomes of type 2 diabetes mellitus (T2DM) on gastric cancer patients following gastrectomy through propensity score matching (PSM) analysis.
A retrospective study of gastric cancer patients following gastrectomy was conducted in a single clinical center from January 2014 to December 2019. The short-term outcomes, overall survival (OS) and disease-free survival (DFS) were analyzed between T2DM group and Non-T2DM group.
A total of 703 patients were enrolled in this study. After 1:1 PSM, 84 patients in T2DM group and 84 patients in Non-T2DM were matched for final analysis. No significant difference was found in terms of operation time, intra-operative blood loss, retrieved lymph nodes, postoperative stay, blood transfusion and complications between T2DM group and Non-T2DM group ( > 0.05). The Kaplan-Meier curve implied that T2DM had no impact on OS or DFS. Cox regression was conducted to identify predictive factors for prognosis. Body mass index (BMI) ( = 0.039 < 0.05, HR = 0.725, 95% CI = 0.534-0.983), pre-operative lymphocyte ( = 0.017 < 0.05, HR = 0.678, 95% CI = 0.493-0.932), pathological tumor node metastasis (pTNM) stage ( = 0.000 < 0.05, HR = 2.619, 95% CI = 2.048-3.349) and complications ( = 0.006 < 0.05, HR = 1.528, 95% CI = 1.132-2.061) were predictive factors for OS, and BMI ( = 0.013 < 0.05, HR = 0.524, 95% CI = 0.315-0.872), pTNM stage ( = 0.000 < 0.05, HR = 2.619, 95% CI = 2.048-3.349) and complications ( = 0.008 < 0.05, HR = 1.892, 95% CI = 1.179-3.036) were independent predictive factors for DFS.
T2DM did not have an impact on gastric cancer patients following gastrectomy in terms of short-term outcomes and prognosis.
本研究旨在通过倾向评分匹配（PSM）分析探讨2型糖尿病（T2DM）对胃癌患者胃切除术后结局的影响。
对2014年1月至2019年12月在单个临床中心接受胃切除术后的胃癌患者进行回顾性研究。分析T2DM组和非T2DM组之间的短期结局、总生存期（OS）和无病生存期（DFS）。
本研究共纳入703例患者。经过1:1 PSM后，T2DM组84例患者与非T2DM组84例患者进行匹配以进行最终分析。T2DM组和非T2DM组在手术时间、术中出血量、清扫淋巴结数、术后住院时间、输血和并发症方面均未发现显著差异（P>0.05）。Kaplan-Meier曲线表明T2DM对OS或DFS无影响。进行Cox回归以确定预后的预测因素。体重指数（BMI）（P=0.039<0.05，HR=0.725，95%CI=0.534-0.983）、术前淋巴细胞（P=0.017<0.05，HR=0.678，95%CI=0.493-0.932）、病理肿瘤淋巴结转移（pTNM）分期（P=0.000<0.05，HR=2.619，95%CI=2.048-3.349）和并发症（P=0.006<0.05，HR=1.528，95%CI=1.132-2.061）是OS的预测因素，BMI（P=0.013<0.05，HR=0.524，95%CI=0.315-0.872）、pTNM分期（P=0.000<0.05，HR=2.619，95%CI=2.048-3.349）和并发症（P=0.008<0.05，HR=1.892，95%CI=1.179-3.036）是DFS的独立预测因素。
T2DM对胃癌患者胃切除术后的短期结局和预后无影响。
